Wesley D. Sterman

President, Chief Executive Officer & Director at Signature Therapeutics, Inc.

Wesley D. Sterman

Wesley D. Sterman

President, Chief Executive Officer & Director at Signature Therapeutics, Inc.

Overview
Career Highlights

Signature Therapeutics, Inc.
Heartport, Inc.
EndoVascular Technologies, Inc.

RelSci Relationships

413

Number of Boards

3

Contact Data
Trying to get in touch with Wesley D. Sterman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Wesley D. Sterman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founding Governor at The City Club of San Francisco, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Signature Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Innoviva, Inc.

Relationship likelihood: Strong

Founding Partner at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP

Relationship likelihood: Strong

Founder at Ensysce Biosciences, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Ensysce Biosciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Chairman of the Board at Theravance Biopharma, Inc.

Relationship likelihood: Strong

Head-Finance at Signature Therapeutics, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Elysium Therapeutics, Inc.

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at Theravance Biopharma, Inc.

Relationship likelihood: Strong

Paths to Wesley D. Sterman
Potential Connections via
Relationship Science
You
Wesley D. Sterman
President, Chief Executive Officer & Director at Signature Therapeutics, Inc.
Education
MD

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

MBA

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Career History
President, Chief Executive Officer & Director
Current

Signature Therapeutics, Inc. develops and manufactures pharmaceutical products. It focuses on developing medications for use in pain management and ADHD. Its proprietary BIO-MD platform is designed to deter prescription drug abuse by virtue of strong chemical bonds within the prodrug and also offers solution to the ongoing epidemic of prescription opioid drug abuse. The company was founded by Steven L. Shafer in 2004 and is headquartered in Palo Alto, CA.

Voluntary Instructor
Current

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Director
1996 - Prior

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.

Boards & Committees
Director
1996 - Prior

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.

Political Donations
$500
2002

Former Assistant at Georgia Court of Appeals

$1,000
2002

Senior Director-Government Law & Policy Practice at Greenberg Traurig LLP

$1,000
2002
Investments
Details Hidden

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Wesley D. Sterman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Wesley D. Sterman's profile does not indicate a business or promotional relationship of any kind between RelSci and Wesley D. Sterman.